Published December 19, 2020 | Version v1
Journal article Open

Descripción del sistema CRISPR-Cas y su aplicación como metodología de punto de cuidado en la detección del SARS-CoV-2

Authors/Creators

  • 1. Centro de Investigación en Ciencias Microbiológicas, Posgrado en Microbiología. Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla, México
  • 2. Escuela de Ingeniería en Mecatrónica de la Universidad Politécnica de Tlaxcala, Tlaxcala, México

Description

RESUMEN

El virus del síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) se propagó a nivel mundial desde diciembre del 2019, causando rápidamente la enfermedad del COVID-19 en el mundo haciendo vulnerable a la población en general. Demostrando su efecto en todas las edades, dañando muchos órganos y sistemas humanos, causando preocupación entre los individuos afectando la vida diaria y la economía mundial. Especialmente, porque no se dispone de vacunas hasta el momento, generando una necesidad sin precedentes de la creación de métodos de diagnóstico para la detección rápida, sensible y que diferencien las cepas del coronavirus. Motivo por el cual, el objetivo del presente estudio fue describir el sistema CRISPR-Cas, así como las metodologías emergentes para la identificación del SARS-CoV-2 y a su vez comparar las ventajas y desventajas de los diversos estudios publicados. Con la finalidad de obtener información de las nuevas tecnologías alternativas basadas en CRISPR-Cas, que en algunos casos han sido aprobadas por la FDA como metodologías de diagnóstico, encontradas en etapas de desarrollo y de prueba en personas enfermas con el COVID-19. Y son comparables con los métodos convencionales de detección del virus, además son un tipo de biosensor de punto de cuidado porque ofrecen un diagnostico efectivo de la enfermedad a gran escala en personas portadoras del SARS-CoV-2.

 

ABSTRACT

The severe acute respiratory syndrome virus coronavirus 2 (SARS-CoV-2) spread since December 2019 causing the disease called “COVID-19” in the world, making the general population vulnerable. Proving its effect in all ages, damaging many human organs and systems, causing preoccupation among the individuals, affecting daily life and the world economy. Specially because vaccines are not available so far, generating an unprecedented need for diagnostic methods for rapid and sensitive detection that differentiates strains of the coronavirus. Reason why the objective of this study was to describe the CRISPR-Cas system, as well as the emerging methodologies for the identification of SARS-CoV-2 and compare the advantages and disadvantages of the various published studies. In order to obtain information on the new alternative technologies based on the CRISPR-Cas that in some cases have been approved by the FDA as a diagnostic methodology, in the development and testing stages in illness people with COVID-19. And are comparable with conventional virus detection methods, are a type of point-of-care biosensor because they offer an effective diagnosis of the disease on a large scale in people carrying SARS-CoV-2.

Files

6) Escobar-Muciño et al Crispercas.pdf

Files (1.9 MB)

Name Size Download all
md5:ca7e065727d4159e91cf54c5cdf8d281
1.9 MB Preview Download

Additional details

Identifiers

ISSN
2594-0627
URL
https://www.aytbuap.mx/aytbuap-520/descripci%C3%B3n-del-sistema-crispr-cas-y-su-aplicaci%C3%B3n-como-metodolog%C3%ADa-de-punt
URL
https://eoi.citefactor.org/10.11235/BUAP.05.02.04

Related works

Is identical to
Journal article: https://repositorioinstitucional.buap.mx/handle/20.500.12371/9782 (URL)

References

  • Fathizadeh H., Maroufi P., Momen-Heravi M., Dao S, Köse Ş, Ganbarov K, Kafil HS. Protection and disinfection policies against SARS-CoV-2 (COVID-19). Infez Med. 2020; 28(2): 185-91.
  • Hou T, Zeng W, Yang M, Chen W, Ren L, Ai J, Wang X. Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19. PLoS Pathog. 2020; 16(8): 1-12.
  • Atzrodt CL, Maknojia I, McCarthy RD, Oldfield TM, Po J, Ta KT, Clements TP. A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS Lett. 2020; 287(17): 3633-3650.
  • Sitio web de European Centre for Disease Prevention and Control, disponible en: https://www.ecdc.europa.eu/en/geographical- distribution-2019-ncov-cases. Revisado 5 de octubre 2020.
  • Zhang F, Abudayyeh OO, Gootenberg JS. A protocol for detection of COVID-19 using CRISPR diagnostics. A protocol for detection of COVID-19 using CRISPR diagnostics. Nat. Methods. 2019:1-8.
  • Tsang J, LaManna CM. Open Sharing During COVID-19: CRISPR-Based Detection Tools. CRISPR J. 2020; 3(3): 142-145.
  • Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, Xu A. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. J Infect. 2020; 80(6):1-13.
  • Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang MLW, Greninger AL. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv.2020: 1-21
  • Sitio wen de Food Drugs and administration FDA. Disponible en: https://www.fda.gov/media/139937/download. Revisado 13-10-2020.
  • Santiago I. Trends and innovations in biosensors for COVID‐19 mass testing. Chem Bio Chem. 2020; 21: 1-11.
  • Straiton J. CRISPR vs COVID-19: how can gene editing help beat a virus? Biotechniques. 2020; 69(5):327-329.
  • Zhang Y. CRISPR-Cas13 as an Antiviral Strategy for Coronavirus Disease 2019. CRISPR J. 2020; 3(3): 140-142.
  • Nalawansha D, Samarasinghe K. Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. ACS Pharmacol Transl Sci. 2020; 3(5): 790–800.
  • Gharib Mombeni E, Birhan M, Yousefi M. CRISPR/Cas9 gene editing technology and its application to the coronavirus disease (COVID-19), a review. J Life Sci Biomed. 2020; 10(1): 01-09.
  • Página de la UNAM de los métodos de diagnóstico CRISPR-Cas Disponible en https://www.inmegen.gob.mx/investigacion/lin eas-de- investigacion/proyecto/?id=455&l=genomica- y-enfermedades-infecciosas. Revisado 7 de septiembre de 2020.
  • Hamid H, Khurshid Z, Adanir N, Zafar MS, Zohaib S. COVID-19 Pandemic and Role of Human Saliva as a Testing Biofluid in Point-of-Care Technology. Eur J Dent. 2020: 1-2.
  • Kalafat E, Yaprak E, Cinar G, Varli B, Ozisik S, Uzun C, Azap A, Koc A. Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet Gynecol. 2020; 55(6): 835-837.
  • Augustine R, Hasan A, Das S, Ahmed R, Mori Y, Notomi T, Kevadiya BD, Thakor AS. Loop-Mediated Isothermal Amplification (LAMP): A Rapid, Sensitive, Specific, and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of COVID-19 Pandemic. Biology. 2020; 9(8):182.
  • Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020; 323(22): 2249-2251.
  • Van Dongen JE, Berendsen JTW, Steenbergen RDM, Wolthuis RMF, Eijkel JCT, Segerink LI. Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities. Biosens Bioelectron. 20; 166:112445.
  • Zhu H, Zhang H, Ni S, Korabečná M, Yobas L, Neuzil P. The vision of point-of-care PCR tests for the COVID-19 pandemic and beyond. Trends Analyt Chem. 2020; 130:1-13.
  • Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, Flament T., et al. Follow-up of adults with non-critical COVID-19 two months after symptoms' onset. Clin Microbiol Infect. 2020; 5:1-6.
  • Bongiovanni M. COVID-19 reinfection in an heltcare worker. J Med Virol. 2020: 1-3.
  • Singer AJ, Ardise J, Gulla J, Cangro J. Point-of-care testing reduces length of stay in emergency department chest pain patients. Ann Emerg Med. 2005; 45(6):587-91.
  • Laskar P, Yallapu MM, Chauhan SC. "Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. Diseases. 2020; 8(30): 1-30.
  • Shiri I. A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease. Nucl Med Commun. 2020; 41:837–840.
  • Hille F, Richter H, Wong SP, Bratovič M, Ressel S, Charpentier E. The biology of CRISPR-Cas: backward and forward. Cell. 2018; 172(6): 1239-1259.
  • Dipali G. Sashital. Pathogen detection in the CRISPR–Cas era. Genome Med. 2018; 10(32):1-4.
  • Sitio web de UniProt disponible en: https://www.uniprot.org/. Revisado 5 de octubre 2020.
  • Wang X, Shang X, Huang X. Next-generation pathogen diagnosis with CRISPR/Cas-based detection methods. Emerg Microbes Infect. 2020a; 9(1): 1682-1691.
  • Terns MP, Terns RM. CRISPR-based adaptive immune systems. Curr Opin Microbiol. 2011;14 (3):321-327.
  • Xiang X, Qian K, Zhang Z, Lin F, Xie Y, Liu Y, Yang Z. CRISPR-Cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia. J Drug Target. 2020:1-10.
  • Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection. ARN. 2020; 26 (7): 771-783.
  • Wang X, Xiong E, Tian T, Cheng M, Lin W, Wang H, Zhang G, Sun J, Zhou X. Clustered regularly interspaced short palindromic repeats/cas9-mediated lateral flow nucleic acid assay. ACS Nano. 2020;14(2):2497–2508.
  • Kumar P, Malik YS, Ganesh B, Rahangdale S, Saurabh S, Natesan S, Srivastava A, Sharun K, Yatoo MI, Tiwari R, Singh RK and Dhama K. CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics. Front Cell Infect Microbiol. 2020; 10:1-13.
  • Johnson ER, McKay DB. Crystallographic structure of the amino terminal domain of yeast initiation factor 4A, a representative DEAD-box RNA helicase. RNA. 1999; 5(12):1526- 1534.
  • Haft DH, Selengut J, Mongodin EF, Nelson KE. A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS Comput Biol. 2005;1(6):474-483.
  • Swarts DC, van der Oost J, Jinek M. Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a. Mol Cell. 2017; 66 (2): 221-233.
  • Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, Anders C, Hauer M, Zhou K, Lin S, Kaplan M, Iavarone AT, Charpentier E, Nogales E, Doudna JA. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Sci. 2014; 343 (6176): 1247997.
  • Sinkunas T, Gasiunas G, Waghmare SP, Dickman MJ, Barrangou R, Horvath P, Siksnys V. In vitro reconstitution of Cascade‐mediated CRISPR immunity in Streptococcus thermophilus. EMBO rep. 2013; 32(3): 385-394.
  • He L, St John James M, Radovcic M, Ivancic-Bace I, Bolt EL. Cas3 Protein—A review of a multi-tasking machine. Genes. 2020; 11(2): 208.
  • Gong B, Shin M, Sun J, Jung CH, Bolt EL, van der Oost J, Kim JS. Molecular insights into ADN interference by CRISPR-associated nuclease-helicase Cas3. Proc Natl Acad Sci U S A. 2014; 111:16359-16364.
  • Huo Y, Nam KH, Ding F, Lee H, Wu L, Xiao Y, Farchione MD Jr, Zhou S, Rajashankar K, Kurinov I, Zhang R, Ke A. Structures of CRISPR Cas3 offer mechanistic insights into Cascade-activated DNA unwinding and degradation. Nat Struct Mol Biol. 2014; 21(9):771-7.
  • Sitio Web de Pfam disponible en: https://Pfam.xfam.org/family/PF16592. Revisado en 14-10-2020.
  • Kouranov A, Xie L, de la Cruz J, Chen L, Westbrook J, Bourne PE, Berman HM. The RCSB PDB information portal for structural genomics. Nucleic Acids Res. 2016; 34:302-305.
  • Gosavi G, Yan F, Ren B, Kuang Y, Yan D, Zhou X, Zhou H. Applications of CRISPR technology in studying plant-pathogen interactions: overview and perspective. Phytopathol Res. 2020;2 (1), 1-9.
  • Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014; 32(4):347-55.
  • Xu W, Jin T, Dai Y, Liu CC. Surpassing the detection limit and accuracy of the electrochemical DNA sensor through the application of CRISPR Cas systems. Biosens Bioelectron. 2020; 155: 1-7.
  • Nishimasu H, Cong L, Yan WX, Ran FA, Zetsche B, Li Y, Kurabayashi A, Ishitani R, Zhang F, Nureki O. Crystal Structure of Staphylococcus aureus Cas9. Cell. 2015; 162(5): 1113-1126.
  • Nishimasu H., Ishitani R., Nureki O. 5AXW, Crystal structure of Staphylococcus aureus Cas9 in complex with sgRNA and target DNA (TTGGGT PAM). Disponible en: https://www.rcsb.org/structure/5AXW.
  • Tang Y, Fu Y. Class 2 CRISPR/Cas: an expanding biotechnology toolbox for and beyond genome editing. Cell Biosci. 2018; 8(59): 1-13.
  • Modelo Cas12. Disponible en: https://bsse.ethz.ch/platt/resources/transcriptio nal-programming-with-sit-cas12.html. Revisado en 14-10-2020.
  • Yan WX, Hunnewell P, Alfonse LE, Carte JM, Keston-Smith E, Sothiselvam S, Cheng DR. Functionally diverse type V CRISPR-Cas systems. Sci. 2019; 363(6422): 88-91.
  • Stella S, Mesa P, Thomsen J, Paul B, Alcón P, Jensen SB, Montoya, G. Conformational activation promotes CRISPR-Cas12a catalysis and resetting of the endonuclease activity. Cell. 2018;175(7):1856-1871.
  • Montoya G, Mesa P, Stella S. 6GTF: Transient state structure of CRISPR-Cpf1 (Cas12a) I5 conformation. Disponible en: https://www.rcsb.org/structure/6GTF.
  • Slaymaker IM, Mesa P, Kellner MJ, Kannan S, Brignole E, Koob J, Strecker J. High-resolution structure of Cas13b and biochemical characterization of ARN targeting and cleavage. Cell rep. 2019; 26 (13): 3741-3751.
  • Zhang Y. CRISPR-Cas13 as an Antiviral Strategy for Coronavirus Disease 2019. CRISPR J.2020; 3, (3):140.
  • Jia N, Meeske AJ, Marraffini LA, Patel. Cryo-EM structure of Cas13(crRNA). Disponible en: https://www.rcsb.org/structure/6VRC.
  • DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsletter on protein crystall. 2002; 40(1):82-92.
  • Ren J, Wen L, Gao X, Jin C, Xue Y, Yao X. DOG 1.0: illustrator of protein domain structures. Cell Res. 2009;19(2):271-273.
  • Aquino-Jarqui G. CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic. Nanomedicina. 2019; 18:428-431
  • Harrington LB, Burstein D, Chen JS, Paez-Espino D, Ma E, Witte IP, DouADN JA. Programmed ADN destruction by miniature CRISPR-Cas14 enzymes. Sci. 2018; 362(6416): 839-842.
  • Savage DF. Cas14: Big Advances from Small CRISPR Proteins. Biochem. 2019; 58(8):1024-1025.
  • Pruitt KD, Tatusova T, Maglott D. R. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2007; 35:61-65.
  • Zuckerkandl E, Pauling L. Evolutionary divergence and convergence in proteins. NY: Academic Press. 1965: 97-166.
  • Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. Mol Biol Evol. 2018; 35:1547-1549.
  • Saitou N, Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987; 4:406-425.
  • Petri, K, Pattanayak V. SHERLOCK and DETECTR open a new frontier in molecular diagnostics. CRISPR J. 2018;1(3):209-211.
  • Yoshimi K, Takeshita K, Yamayoshi S, Shibumura S, Yamauchi Y, Yamamoto M, Mashimo T. Rapid and accurate detection of novel coronavirus SARS-CoV-2 using CRISPR-Cas3. medRxiv. 2020: 1-30.
  • Lira CR., De la Cruz PJ, Maldonado RA, Rojas Montes O. Sistemas de amplificación isotérmica para la detección molecular de los virus zika, dengue y chikungunya. Mens Bioquim. 2018; 42: 92-102.
  • López Casillas F. CRISPR, el sueño divino hecho realidad. Rev Fac Med Univ Nac Auton Mex. 2015; 58(4): 55-60.
  • Azhar M, Phutela R, Kumar M, Ansari AH, Rauthan R, Gulati S, Acharya, S. Rapid, accurate, nucleobase detection using FnCas9. medRxiv. 2020:1-28.
  • Azhar M, Phutela R, Ansari AH, Sinha, D. Sharma N, Kumar M, Patra PK. Rapid, field-deployable nucleobase detection and identification using FnCas9. bioRxiv. 2020: 1-28.
  • Nguyen LT, Smith BM, Jain PK. Enhancement of trans-cleavage activity of Cas12a with engineered crARN enables amplified nucleic acid detection. bioRxiv.2020: 1-15.
  • Yuan T, Mukam O, Li Z, Chen W, Zhang Y, de Dieu Habimana J, Zeng L. A rapid and sensitive CRISPR/Cas12a based lateral flow biosensor for the detection of Epstein–Barr virus. Analyst. 2020; 145: 6388-6394.
  • Ali Z, Aman R, Mahas A, Rao GS, Tehseen M, Marsic T, Pain A. iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Res. 2020; 288:198129.
  • Wang X, Zhong M, Liu Y, Ma P, Dang L, Meng Q, Yang Z. Rapid and sensitive detection of COVID-19 using CRISPR/Cas12a-based detection with naked eye readout, CRISPR/Cas12a-NER. Sci Bull. 2020; 65(17): 1436–1439.
  • Ding X, Yin K, Li Z, Liu C. All-in-One dual CRISPR-cas12a (AIOD-CRISPR) assay: a case for rapid, ultrasensitive and visual detection of novel coronavirus SARS-CoV-2 and HIV virus. bioRxiv. 2020:1-5.
  • Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang, F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat protoc. 2019;14(10): 2986-3012.
  • Arizti-Sanz J, Freije CA, Stanton AC, Boehm CK, Petros BA, Siddiqui S. Gross, R. Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2. bioRxiv. 2020: 1-15.
  • Nieuwenweg AC, Van GMM, Horsting A, Hegge JW, Velders A, Saggiomo V. CRISPR-Clear: A Fieldable Detection Procedure for Potential CRISPR-Cas9 Gene Drive Based Bioweapons. Chemrxiv.2019: 1-21.
  • Katzmeier F, Aufinger L, Dupin A, Quintero J, Lenz M, Bauer L, Styazhkin I. A low-cost fluorescence reader for in vitro transcription and nucleic acid detection with Cas13a. PloS one. 2019; 14(12): 1-17.
  • Choi JR. Development of Point-of-Care Biosensors for COVID-19. Front Chem. 2020;8(517):1-10.
  • Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020:26:1200–1204.
  • Thi VLD, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. Sci Transl Med. 2020;12(556):1-15.
  • Mohan A, Chandra S., Agarwal D, Guleria R, Broor S, Gaur B, Mohan Pandey R. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: A systematic review. Respirology. 2010; 15:536–542.
  • Smyrlaki I, Ekman M, Lentini A, Rufino de Sousa N, Papanicolaou N, Vondracek M., et al. Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR. Nat Commun. 2020;11(1): 4812.
  • Centers for Disease Control and Prevention. Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus. Disponible en: https://www.cdc.gov/coronavirus/2019- ncov/downloads/rt-pcr-panel-for-detection- instructions.pdf. Revisado el 20 noviembre de 2020.
  • Centers for Disease Control and Prevention. Information for Laboratories: 2019-nCoV | CDC. Acceptable Commercial Primers and Probes. Disponible en: https://www.cdc.gov/coronavirus/2019- ncov/lab/index.html. Revisado el 20 noviembre de 2020.
  • Gill P, Ghaemi A. Nucleic acid isothermal amplification technologies-A review. Nucleosides nucleotides. Nucleic acids.2008; 27: 224-43.
  • Sánchez E, Nina M, Aguirre P, Arce M, Toro N, Vilela R. Amplificación isotérmica mediada por LOOP (LAMP) de ácidos nucleicos en el diagnóstico clínico. Rev Cs Farm y Bioq. 2014; 2 (1):1125-1138.
  • Morisaka H, Yoshimi, K, Okuzaki Y., et al. CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun. 2019; 10 (5302): 1-13.
  • Broughton JP, Deng X, Yu G., et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020; 38(7): 870–874.
  • Belavi C. Desarrollo de reactivos para la detección cuantitativa del gen de fusión pml-rara mediante PCR en tiempo real. XIX encuentro de jóvenes investigadores de la UNL, Arg. Octubre 14- 15. 2015.
  • Sitio web de la Secretaría de Salud México. Disponible en: https://www.facebook.com/SecretariadeSalud MX/photos/pcb.3463004997081502/34630045 87081543/. Revisado 18 de noviembre de 2020.
  • Aramburu A, Huaroto F, Reyes N. Precisión diagnóstica de pruebas basadas en amplificación isotérmica mediada en lazo de transcriptasa inversa (RT-LAMP) para SARS-CoV-2. Serie Revisiones rápidas, Ministerio de Salud, Instituto Nacional de Salud de Lima. 2020; 8:1-26.
  • Patchsung M, Jantarug K, Pattama A., et al. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat Biomed Eng. 2020.
  • Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell. 2020;181(4):865-876.
  • Hou T, Zeng W, Yang M, Chen W, Ren L, Ai J., et al. Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19. PLoS Pathog. 2020; 16(8): e1008705
  • Ackerman CM, Myhrvold C, Thakku S G, Freije CA, Metsky HC, Yang DK., et al. Massively multiplexed nucleic acid detection with Cas13. Nat. 2020; 582: 277–282.
  • Azmi I, Faizan MI, Kumar R, Yadav, S. R, Chaudhary N, Singh K, et al. A saliva-based RNA extraction-free workflow integrated with Cas13a for SARS-CoV-2 detection. medRxiv. 2020: 1-39.
  • Fozouni P, Son S, de León Derby MD, Knott GJ, Gray CN, D'Ambrosio MV, et al. Direct detection of SARS-CoV-2 using CRISPR-Cas13a and a mobile phone. MedRxiv. 2020.
  • Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang MLW., et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv.2020
  • Brandsma E, Verhagen HJ, van de Laar TJ, Claas EC, Cornelissen M, Van den AE. Rapid, sensitive and specific SARS coronavirus-2 detection: a multi-center comparison between standard qRT-PCR and CRISPR based DETECTR. medRxiv. 2020.
  • Wu X, Chan C, Lee YH, Springs SL, Lu TK, Yu H. A Digital CRISPR-based. medRxiv. 2020.
  • Ali Z, Aman R, Mahas A, Rao GS, Tehseen M, Marsic T., et al. iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus res. 2020; (288):198129.
  • Rauch JN, Valois E, Ponce-Rojas JC, Aralis Z, Lach RS, Zappa F., et al. Rapid CRISPR-based surveillance of SARS-CoV-2 in asymptomatic college students captures the leading edge of a community-wide outbreak. medRxiv. 2020.
  • Azhar M, Phutela R, Kumar M, Ansari AH, Rauthan R, Gulati S., et al. Rapid, accurate, nucleobase detection using FnCas9. medRxiv. 2020.
  • Huang Z, Tian D, Liu Y, Lin, Lyon C, Lai W, Ning B. Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis. Biosens Bioelectron. 2020; 164: 112316.
  • Santiago-Frangos A, Hall LN, Nemudraia A, Nemudryi A, Krishna P, Wiegand T, et al. Intrinsic Signal Amplification by Type-III CRISPR-Cas Systems Provides a Sequence-Specific Viral Diagnostic. medRxiv. 2020.
  • Huang W, Yu L, Wen D, Wei D, Sun Y., Zhao H., et al. A CRISPR-Cas12a-based specific enhancer for more sensitive detection of SARS-CoV-2 infection. medRxiv. 2020.
  • Konwarh R. Can CRISPR/Cas technology be a felicitous stratagem agains the COVID-19 fiasco? Prospects and Hitches. Front Mol Biosci. 2020; 10(7):557377.